期刊文献+

表皮生长因子受体和血管内皮生长因子在非小细胞肺癌中的表达及意义 被引量:6

Expression and clinical significance of epidermal growth factor receptor and vascular endothelial growth factor in non-small cell lung cancer
下载PDF
导出
摘要 目的观察非小细胞肺癌(NSCLC)组织中表皮生长因子受体(EGFR)和血管内皮生长因子(VEGF)的表达情况以及与临床病理参数的关系。方法免疫组织化学法检测76例NSCLC组织和14例非恶性肺组织EGFR和VEGF的表达。结果EGFR和VEGF在76例NSCLC组织中的阳性表达率分别为47.4%(36/76)和51.3%(39/76),在14例非恶性肺组织表达率分别为7.14%(1/14)和7.14%(1/14),两组EGFR、VEGF表达差异显著(P<0.05)。Ⅲ期NSCLC组织的EGFR表达率为56.8%(25/19),高于Ⅰ~Ⅱ期患者的31.3%(10/32),两者差异显著(P<0.05),EGFR表达与其他临床病理参数均无关;淋巴结阳性的NSCLC组织VEGF表达率为77.8%(28/34),明显高于淋巴结阴性的27.5%(11/42),两者差异显著(P=0.000),VEGF表达与肿瘤分期、性别、年龄、肿瘤细胞分化等临床病理参数亦无关。EGFR和VEGF在NSCLC组织中表达无相关性(P>0.05)。结论NSCLC组织中EGFR和VEGF常常为高表达,EGFR表达与肿瘤的TNM分期有关,VEGF与淋巴结转移有关;但是EGFR和VEGF的表达之间无相关性。 Objective To observe the expression of epidermal growth factor receptor(EGFR) and vascular endothelial growth factor(VEGF) in non-small cell lung cancer(NSCLC) and correlated with clinicopathologic parameters. Methods HE staining of paraffin sections was used to study lymph node metastatic status. Immunohistoehemistry of tissue sections was used to study the expression of EGFR and VEGF in seventy-six NSCLC tissues and 14 cases of normal lung samples. Results The positive rates of EGFR and VEGF in 76 NSCLC samples were obviously higher than those in the 14 normal lung samples(47.4% vs. 7.14% for EGFR, 51.3% vs. 7. 14% for VEGF, P 〈0. 05). The positive rate of EGFR with stage Ⅲ was higher than that with stage Ⅰ/Ⅱ(56. 8% vs. 31.3% , P 〈 0. 05 ). The positive rate of VEGF with lymph node metastasis was higher than that without lymph node metastasis ( 77.8% vs. 27.5% ,P = 0. 000). EGFR and VEGF expression was not statistically correlated with each other. Conclusion EGFR and VEGF were overexpressed in NSCLC tissues. The expression of EGFR in NSCLC was correlated with TNM stages. The expression of VEGF in NSCLC was correlated with lymph node metastasis. The expression of EGFR was not correlated with VEGF expression in NSCLC tissues.
出处 《临床肿瘤学杂志》 CAS 2010年第1期26-29,共4页 Chinese Clinical Oncology
关键词 非小细胞肺癌 免疫组织化学 表皮生长因子受体 血管内皮生长因子 Non-small cell lung cancer(NSCLC) Immunohistochemistry Epidermal growth factor receptor(EGFR) Vascular endothelial growth factor(VEGF)
  • 相关文献

参考文献8

  • 1Ahmedin J, Rebecca S, Elizabeth W, et al. Cancer Statistics, 2009[J]. CA Cancer J Clin, 2009, 59:225 -249.
  • 2Mendelsohn J, Baselga J. Status of epidermal growth factor receptor antagonists in the biology and treatment of cancer [ J ]. J Clin Oncol, 2003, 21 (14) :2787 -2799.
  • 3Ettinger DS. Clinical implications of EGFR expression in the development and progression of tumors: focus on non small celt lung cancer[J]. Oncologist, 2006, 11:358 -373.
  • 4Fukuoka M, Wu Y, Thongprasert S, et al. Biomarker analyses from a phase Ⅲ, randomized, open-label, first-line study of gefitinib (G) versus carboplatin/paclitaxel (C/P) in clinically selected patients ( pts ) with advanced non-small cell lung cancer (NSCLC) in Asia(IPASS)[J].J Clin Oncol, 2009, 27,15 (Sappl) : a$006.
  • 5Kaya A, Ciledag A, Gulbay BE, et al. The prognostic significance of vascular endothelial growth factor levels in sera of non small cell lung cancer patients[ J]. Respir Med, 2004, 98 : 632 - 636.
  • 6Li J, Hong M, Pan T. Clinical significance of VEGF-C and VEGFR-3 expression in non-small cell lung cancer [ J ]. J Hua zhong Univ Sei Technolog Med Sci, 2006, 26:587 -590.
  • 7Saintigny P, Kambouchner M, Ly M, et al. Vascular endothelial growth factor-C and its receptor VEGFR-3 in non-small-cell lung cancer: concurrent expression in cancer cells from primary tumor and metastatic lymph node [ J ]. Lung Cancer, 2007, 58 ( 2 ) : 205 - 213.
  • 8Byers LA, Heymach JV. Dual targeting of the vascular endothelial growth factor and epidermal growth factor receptor pathways: rationale and clinical applications for non-small-cell lung cancer [ J ]. Clin Lung Cancer,2007,8 ( Suppl 2 ) : 79 - 85.

同被引文献67

  • 1许良中,杨文涛.免疫组织化学反应结果的判断标准[J].中国癌症杂志,1996,6(4):229-231. 被引量:1365
  • 2滕月娥,李午生,金峰,刘云鹏,徐惠绵.胃癌组织COX-2、VEGF-C表达与淋巴结转移及预后关系的研究[J].中国肿瘤临床,2005,32(11):607-610. 被引量:22
  • 3孙晓杰,黄常志.PI3K-Akt信号通路与肿瘤[J].世界华人消化杂志,2006,14(3):306-311. 被引量:80
  • 4胡雪君,宋娜,刘云鹏,马艳菊,郝艳艳,康健.EGFR、VEGF和COX-2在非小细胞肺癌中的表达和意义[J].实用肿瘤杂志,2007,22(3):209-213. 被引量:19
  • 5Lynch TJ, Bell DW, Sordella R, et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small- cell lung cancer to gefitinib[J]. N Engl J Med, 2004,350: 2129- 2139.
  • 6Przybojewska B, Rydzynski K, Stepnik M, et al. Immunohistochemical evaluation of p21ras and p53 proteins expression in human non-small cell lung cancers [ J ]. Neoplasma,2003,50:198-203.
  • 7Miyatake K, Gemba K, Ueokda H, et al. Prognostic significance of mutant p53 protein, P-glycoprotein and glutathione S-transferase-pi in patients with unresectable non-small cell lung cancer [J].Anticancer Res,2003,23:2829-2836.
  • 8Tsao MS, Aviel-Ronen S, Ding K, et al.Prognostie and predictive importance of p53 and RAS for adjuvant chemotherapy in non small-cell lung cancer [J].J Clin Oncol,2007,25:5240-5247.
  • 9Takahash K, Takahash F, Hirama M,et al.Restoration of CD44S in non-small cell lung cancer cells enhanced their susceptibility to themacrophage cytotoxicity[J]. Lung cancer,2003, 41: 145-153.
  • 10Mendelsohn J, Baselga J. Status of epidermal growth factor receptor antagonists in the biology and treatment of cancer [J]. J Clin Oncol, 2003.21 : 2787- 2799.

引证文献6

二级引证文献25

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部